InvestorWire NewsRoom

Article

CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials
February 12, 2021

CNS Pharmaceuticals (NASDAQ: CNSP) Celebrates IND Status, Prepares to Launch Brain Cancer Drug Trials

  • Brain cancer drug developer CNS Pharmaceuticals is celebrating recent news that the U.S. Food and Drug Administration (“FDA”) granted investigational new drug (“IND”) status to CNS Pharmaceuticals’ leading candidate for fighting glioblastomas
  • Glioblastomas are a class of aggressive brain cancers with no known cure and a median life expectancy of 14 to 16 months following diagnosis
  • The FDA’s decision to grant CNSP’s request for IND status clears the way for the company to begin human clinical trials within the next couple of months
  • The company’s sublicensee partner, WPD Pharmaceuticals, will also prepare a first-ever Phase I trial for drug safety in children, planned later this year in Poland

During the last year the COVID-19 pandemic has occupied large headlines worldwide while small neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) has been quietly building a newsworthy effort of its own to improve a select group of individuals’ lives, preparing to launch medical trials that could help end the unrelenting and ultimately fatal advance of glioblastoma brain cancers.

CNSP acquired the worldwide exclusive licensing to its leading drug candidate Berubicin, an anthracycline that has demonstrated its potential in fighting off glioblastomas and a stand-out drug among other anthracyclines because of its apparent ability to effectively cross the blood-brain barrier and target central nervous system malignancies.

In a January podcast interview, company CEO John Climaco showed his excitement at news the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status, clearing the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators.

“This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials. … We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound.” 

The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat.

Berubicin’s “powerhouse” potential was demonstrated in an initial Phase 1 trial completed by another company well over a decade ago. Within the very limited pool of participants in the trial, 44 percent saw their disease stabilize or even begin to improve. One patient emerged cancer-free and as of the most recent medical assessment last year was still alive and still in remission 14 years after the Phase 1 trial — a remarkable exception to the rule that the vast majority of glioblastoma patients will be dead within 14 to 16 months of diagnosis.

CNSP’s planned Phase 2 trials will use a much larger pool of 243 patients for its real-time comparison of Berubicin’s performance against the “standard of care” chemotherapy drug lomustine in side-by-side brackets that compare the 162 Berubicin users with 81 lomustine users. The trials will take place in about 60 research centers scattered across North America, Europe and the Asia-Pacific region to help deliver a diverse representation of individuals (https://ibn.fm/4sWQi).

While the adult trials are taking place, CNSP’s sublicensee partner for testing will also be preparing a first-ever Phase I trial for drug safety in children who have glioblastomas and have already failed to see a significant turnaround with standard-of-care medications. The pediatric trial is slated to begin later in the year in Poland.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).